Long-Duration Levodopa Response Distinguishes Parkinson's, Predicts Outcomes

Distinguishing Parkinson's disease (PD) from atypical parkinsonian syndromes like multiple system atrophy (MSA) and progressive supranuclear palsy (PSP) remains a persistent clinical challenge, particularly in early disease stages when symptoms overlap [1]. While a robust response to levodopa has long been a clinical hallmark of PD, its utility is not absolute [2]. Systematic reviews show that a significant minority of patients with pathologically confirmed PD have a poor or non-existent response, with some studies reporting 4.6% showing a poor response and 26.9% being non-responsive [2]. Complicating matters further, some patients with atypical parkinsonism may exhibit a transient response, and dopaminergic imaging can show variable deficits across these disorders [3]. This diagnostic ambiguity can delay appropriate management and prognostic counseling [4, 5]. A recent study provides a detailed, pathology-confirmed analysis of levodopa response, clarifying its diagnostic and prognostic value across these conditions.